Nanobiotix S.A Share Holder Equity 2020-2024 | NBTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Nanobiotix S.A share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Nanobiotix S.A share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.3B
Zoetis (ZTS)	$67.2B
Daiichi Sankyo, - (DSNKY)	$46.3B
Takeda Pharmaceutical (TAK)	$45.6B
BeOne Medicines - (ONC)	$33.5B
Sandoz Group AG (SDZNY)	$26B
Summit Therapeutics (SMMT)	$19.9B
Merck (MKKGY)	$16.9B
Shionogi (SGIOY)	$14.3B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.3B
Orion OYJ (ORINY)	$11.4B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.7B
Corcept Therapeutics (CORT)	$7.2B
Grifols, S.A (GRFS)	$7.2B
Ionis Pharmaceuticals (IONS)	$6.6B
Madrigal Pharmaceuticals (MDGL)	$6.5B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.2B
Hypermarcas (HYPMY)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B